Showing 8681-8690 of 20878 results for "".
RAS(ON) and Beyond: Clinical Integration and Strategic Sequencing
https://reachmd.com/programs/cme/rason-and-beyond-clinical-integration-and-strategic-sequencing/54124/Explore ON-state RAS inhibitors for the treatment of NSCLC and pancreatic cancer, including mechanisms, efficacy data, and integration into clinical practice.Long-term improvements in daily steps with gamification and financial incentives in patients at risk for CV events
https://reachmd.com/programs/acc-action-center/long-term-improvements-in-daily-steps-with-gamification-and-financial-incentives-in-patients-at-risk-for-cv-events/24347/ACC.24 - Alexander Fanaroff shares the results of the BE ACTIVE trial, which investigated the long-term efficacy of gamification, financial incentives, or a combination of both approaches for increasing physical activity in patients at risk for cardiovascular events.Virtual IBD Clinic: Diagnosis and Medical Treatment
https://reachmd.com/programs/cme/virtual-ibd-clinic-diagnosis-and-medical-treatment/11442/Explore the diagnosis and treatment of a young patient who presents with symptoms that are consistent with inflammatory bowel diseases (IBD).From Abstract to Action in Breast Cancer: Interpreting Recent Data on Oral SERDs and Endocrine Targeting Strategies
https://reachmd.com/programs/cme/from-abstract-to-action-in-breast-cancer-interpreting-recent-data-on-oral-serds-and-endocrine-targeting-strategies/57230/Watch our experts review key ASCO 2026 data on oral SERD therapies in breast cancer and discuss the potential impact on treatment sequencing and patient care.Understanding the Mechanism Behind a Treatment Approach in Indolent Systemic Mastocytosis (ISM)
https://reachmd.com/programs/medical-industry-feature/mechanism-treatment-approach-indolent-systemic-mastocytosis-ism/32766/Historically, indolent systemic mastocytosis (ISM) care focused on treating symptoms. AYVAKIT® (avapritinib) targets the KIT D816V mutation, the underlying cause of ISM.3,4 Learn how AYVAKIT can play a role in treating patients with ISM.1Pruritus In PN and AD: Challenge How You Manage Itch
https://reachmd.com/programs/cme/pruritus-in-pn-and-ad-challenge-how-you-manage-itch/36304/Use validated assessment tools to prioritize and measure itch in prurigo nodularis and atopic dermatitis in an interactive CME escape room.Simple Diagnostic Steps That Change TD Outcomes & Increase Quality of Life
https://reachmd.com/programs/cme/simple-diagnostic-steps-that-change-td-outcomes-increase-quality-of-life/54716/Review standardized screening, symptom recognition, and multidisciplinary management strategies to improve diagnosis and care of tardive dyskinesia.Challenging Cases in IgA Nephropathy and Identifying Patients for Specialized Care
https://reachmd.com/programs/medical-industry-feature/challenging-cases-iga-nephropathy-specialized-care/29536/IgA nephropathy is a heterogeneous disease with variable clinical presentation. Learn more about its pathogenesis, diagnostic considerations, and complex cases as Dr. Jaimini Patel sits down with Dr. Sayna Norouzi, Associate Professor of Medicine and clinical nephrologist at Loma Linda University MeIntegrating Guideline Updates in Squamous Cell Carcinoma of the Anal Canal
https://reachmd.com/programs/project-oncology/guideline-updates-anal-canal-squamous-cell-carcinoma/54280/As NCCN® Clinical Practice Guidelines in Oncology evolve, integrating chemoimmunotherapy into the management of advanced squamous cell carcinoma of the anal canal requires thoughtful, patient-centered decision-making. That’s why Dr. Stacey Cohen joins Dr. Charles Turck to translate updated recommendImplementing Potassium Binders: Practical Dosing and Long-Term Follow Up
https://reachmd.com/programs/cme/tbd/37674/Learn from a multidisciplinary faculty panel how to Improve outcomes for patients with CKD and HFrEF using optimal RAASi and MRAs while managing hyperkalemia with potassium binders.